WITH THE ADVENT OF MONOCLONAL ANTIBODY TECHNOLOGY, TWO THINGS HAVE BECOME INCREASINGLY OBVIOUS: 1.

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 4782
Amount: $47,000.00
Phase: Phase I
Program: SBIR
Awards Year: 1986
Solitcitation Year: N/A
Solitcitation Topic Code: N/A
Solitcitation Number: N/A
Small Business Information
Verax Corp
Etna Road, Hc61, Box 6, Lebanon, NH, 03766
Duns: N/A
Hubzone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 AMAR S TUNG
 PRINCIPAL INVESTIGATOR
 (603) 448-4445
Business Contact
Phone: () -
Research Institution
N/A
Abstract
WITH THE ADVENT OF MONOCLONAL ANTIBODY TECHNOLOGY, TWO THINGS HAVE BECOME INCREASINGLY OBVIOUS: 1. THESE MOLECULESWILL BE NEEDED IN KILOGRAM QUANTITIES FOR THE TREATMENT OF AVARIETY OF MALIGNANCIES. 2. ANTIBODIES OF HUMAN, AND NOT MURINE, ORIGIN WILL ULTIMATELY BE THE MOLECULES OF CHOICE. VERAX HAS BEEN DEVELOPING A NOVEL SYSTEM FOR THE MASS CULTURE OF MURINE HYBRIDOMA CELLS AND NOW WISHES TO EXTEND DEVELOPMENT TO STUDIES OF HUMAN HYBRIDOMA TECHNOLOGY. OF PARTICULAR INTEREST IS AN ANALYSIS OF THE FEASIBILITY OF ADAPTING HUMAN HYBRIDOMA CELLS TO A CELL IMMOBILIZING MATRIXMATERIAL. OTHER GOALS ARE TO DEVELOP MINIMAL CULTURE MEDIUMFOR THE GROWTH OF THESE CELLS AND TO SELECT HIGH IMMUNO- GLOBULIN PRODUCING CLONES FROM LARGE POPULATIONS OF CELLS. WHILE IT MAY SEEM THAT THIS WORK WILL BE A SLIGHT MODIFICATION OF VERAX'S EXISTING TECHNOLOGY, SIGNIFICANT DIFFERENCES WILL EXIST BETWEEN HUMAN/HUMAN AND MOUSE/MOUSE HYBRIDOMAS IN TERMS OF GROWTH AND PRODUCTION POTENTIAL AND DEFINITION OF THESE DIFFERENCES WILL REQIURE CONSIDERABLE TIME AND ENERGY. MOREOVER, IT SEEMS LIKELY THAT THE CONDITIONS NECESSARY FOR EFFICIENT PRODUCTION OF HUMAN MONOCLONAL ANTIBODIES WILL BE DIFFERENT THAN THOSE REQUIRED FOR MOUSE MONOCLONAL ANTIBODIES.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government